Advertisement
A vs SYK
Which Stock Would AI Choose? Agilent Technologies (A) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- Agilent Technologies and Stryker Corporation both operate in healthcare-adjacent markets but serve very different customers: Agilent sells analytical instruments and diagnostics to labs and life-science firms, while Stryker sells medical devices and robotics to hospitals and surgeons.
- Agilent's recent momentum has been notably stronger, with its share price advancing double digits in recent weeks and outpacing Stryker year to date.
- Stryker's recent results reflect a recovery from a first-quarter cybersecurity disruption, with organic sales growth rebounding to roughly 9% in its latest quarter.
- Stryker carries a larger market capitalization (above $100 billion) and a lower earnings multiple than Agilent, while Agilent trades at a higher valuation with faster near-term price appreciation.
- Stryker is navigating a leadership transition, while Agilent has drawn a series of recent analyst upgrades citing improving demand and operating-margin expansion.
- For more detail on each name, explore the A Major News and A Today's Price Move pages, as well as the SYK Major News and SYK Today's Price Move pages.
- To see how AI-driven strategies are positioning across these and other tickers, explore Trending AI Robots.
Introduction
Investors weighing healthcare exposure often encounter two very different business profiles under a single sector label. A (Agilent Technologies) supplies analytical instruments, laboratory consumables, and diagnostics that support drug development and applied chemical testing. SYK (Stryker Corporation) manufactures orthopedic implants, surgical equipment, and robotic-assisted platforms used directly in patient care. This stock comparison is relevant for traders tracking relative performance and momentum, as well as longer-horizon investors evaluating growth durability, sector exposure, and market positioning. Because the two companies respond to different demand cycles and risk factors, contrasting them highlights trade-offs between cyclical innovation spending and steadier procedure-driven healthcare demand.
A Overview and Recent Performance
Agilent Technologies provides application-focused solutions across life sciences, diagnostics, and applied chemical markets. Its instrument portfolio spans liquid and gas chromatography, mass spectrometry, and spectroscopy, alongside consumables and companion diagnostics. In recent weeks, Agilent's share price has shown notable strength, with strong one-month and three-month gains and a positive year-to-date trend that has outpaced the broader market.
Sentiment has been supported by improving demand conditions. Recent quarterly results showed core revenue growth exceeding the high end of guidance, with particular strength in pharma and China, where sales rose ahead of a prior flat-growth expectation. GLP-1-related revenue and advanced materials demand tied to semiconductor applications have added momentum, and the company has logged a book-to-bill ratio above one for ten consecutive quarters. Analysts have responded with upgrades and Buy initiations in recent weeks, citing margin expansion driven by the company's operating-model initiatives.
SYK Overview and Recent Performance
Stryker Corporation is one of the largest medical-device companies globally, operating across MedSurg and Neurotechnology, Orthopaedics, and related product lines including the Mako robotic-surgery platform. Its revenue is tied to hospital capital budgets, procedure volumes, and surgeon adoption of implants and enabling technologies.
Stryker's recent market activity has been more mixed. A cybersecurity incident disrupted global operations earlier in the year, pressuring first-quarter production and sales. By the latest quarter, however, organic sales growth had rebounded to roughly 9%, with adjusted earnings per share (EPS) up nearly 18% year over year and operating margins expanding. Despite this recovery, the stock has lagged on a year-to-date basis and remains below its 52-week highs. The company also recently announced a planned chief executive transition, with its chief operating officer set to succeed the long-serving CEO. Product catalysts such as record Mako installations and new clearances continue to support the growth pipeline, but execution risks remain in focus.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that monitor and trade thousands of different tickers across equity and cryptocurrency markets. Because not every strategy performs equally in every environment, Tickeron curates a dedicated Trending AI Robots section to highlight the bots best suited to current market conditions. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they follow, so investors can screen for approaches that align with their own objectives and risk tolerance. The curated list provides a practical starting point for those who want to observe how algorithmic systems are responding to shifting momentum and volatility rather than researching the full catalog from scratch.
Head-to-Head Comparison
Although both companies are classified within healthcare, their business models diverge sharply. Agilent's revenue is tied to research-and-development budgets, pharmaceutical spending, and capital-equipment replacement cycles, making it more sensitive to biotech funding and global lab demand. Stryker's revenue is anchored in recurring procedure volumes, implant consumption, and hospital capital equipment, giving it a steadier, more defensive demand profile.
On valuation, the two present a clear trade-off. Stryker's larger scale and lower forward earnings multiple reflect its mature, diversified device franchise, and its current multiple sits below its own historical median. Agilent trades at a higher earnings multiple, which implies greater embedded growth expectations. Growth drivers also differ: Agilent leans on pharma demand, China recovery, and semiconductor-adjacent materials, while Stryker leans on robotics adoption, an aging population, and product-launch cadence. Risk profiles diverge as well — Stryker has contended with cyber disruption, supply constraints, and leadership transition, while Agilent faces exposure to cyclical instrument demand and tariff-related costs.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor A in the current environment. Agilent has demonstrated more consistent near-term trend strength, stronger relative performance, and a run of positive catalysts, including improving demand, analyst upgrades, and sustained book-to-bill momentum. Stryker's fundamentals remain solid and its valuation appears more supportive, but its trend has been less consistent amid the cyber recovery and leadership handover. This assessment reflects trend consistency, relative positioning, and catalyst flow rather than a definitive forecast, and it could shift as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and SYK is a StrongBuy.
A's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 21 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 75%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 68 cases where A's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on A as a result. In 50 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 28 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 137 of 209 cases where A Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 13 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.692) is normal, around the industry mean (67.298). P/E Ratio (34.334) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
SYK in upward trend: 10-day moving average broke above 50-day moving average on October 26, 2026
The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on SYK as a result. In 49 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
SYK moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 174 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 128 of 258 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for SYK moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 24 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 59 cases where SYK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.
SYK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.211) is normal, around the industry mean (4.142). P/E Ratio (33.491) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.253). Dividend Yield (0.011) settles around the average of (0.011) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
A | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 71 | 69 | |
SMR RATING 1..100 | 45 | 52 | |
PRICE GROWTH RATING 1..100 | 13 | 49 | |
P/E GROWTH RATING 1..100 | 46 | 79 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for SYK (79) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as A (71) in the Biotechnology industry. This means that SYK’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is in the same range as SYK (52) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
A's Price Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for SYK (49) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than SYK’s over the last 12 months.
A's P/E Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for SYK (79) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than SYK’s over the last 12 months.
| A | SYK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | 1 day ago 63% |
| Stochastic ODDS (%) | 1 day ago 63% | 1 day ago 56% |
| Momentum ODDS (%) | 1 day ago 58% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 64% | N/A |
| TrendWeek ODDS (%) | 1 day ago 65% | 1 day ago 51% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 50% |
| Advances ODDS (%) | 4 days ago 62% | 9 days ago 57% |
| Declines ODDS (%) | 1 day ago 63% | 1 day ago 50% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 54% |
| Aroon ODDS (%) | 1 day ago 66% | 1 day ago 50% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green while SYK’s FA Score has 0 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 2 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- A’s TA Score: 2 bullish, 6 bearish.
- SYK’s TA Score: 5 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +0.72% price change this week, while SYK (@Medical/Nursing Services) price change was -6.77% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.23%. For the same industry, the average monthly price growth was -5.93%, and the average quarterly price growth was +36.61%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.08%. For the same industry, the average monthly price growth was -5.52%, and the average quarterly price growth was -4.54%.
Reported Earning Dates
A is expected to report earnings on Nov 23, 2026.
SYK is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Medical Specialties (-0.23% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+2.08% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.